Clinical trials: Public Speaking
Social Anxiety Disorder (SAD)
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.
- Trial name
- NCT07221578
- Testing
- VQW-765
- Where
- 30 sites in United States
- Volunteers
- 500 people
- Sponsor
- Vanda Pharmaceuticals
Social Anxiety Disorder
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in…
- Trial name
- PALISADE-3 (NCT06358651)
- Testing
- Fasedienol Nasal Spray
- Where
- 24 sites in United States
- Volunteers
- 238 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during…
- Trial name
- Palisade-1 (NCT04754802)
- Testing
- PH94B Nasal Spray
- Where
- 21 sites in United States
- Volunteers
- 224 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to…
- Trial name
- NCT06809179
- Testing
- Fasedienol Nasal Spray - Fasedienol Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder (SAD)
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in…
- Trial name
- PALISADE-4 (NCT06615557)
- Testing
- Fasedienol Nasal Spray
- Where
- 26 sites in United States
- Volunteers
- 238 people
- Sponsor
- VistaGen Therapeutics, Inc.
Depressive Disorder and Anxiety Disorders
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging…
- Trial name
- NCT00343707
- Testing
- vestipitant, paroxetine
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during…
- Trial name
- Palisade-2 (NCT05011396)
- Testing
- PH94B Nasal Spray
- Where
- 15 sites in United States
- Volunteers
- 228 people
- Sponsor
- VistaGen Therapeutics, Inc.